Loading
companiesCompany
Vergent Bioscience
Vergent Bioscience is testing an injectable dye that makes lung tumours glow during keyhole and robotic surgery, so surgeons can find small or hidden tumours and check that all of the cancer has been removed.
Overview
Vergent Bioscience is a clinical-stage company in Minneapolis developing abenacianine for injection (VGT-309), a tumour-targeted fluorescent imaging agent for minimally invasive and robotic-assisted cancer surgery. Abenacianine is a quenched activity-based probe that binds cathepsin proteases overexpressed in tumours and fluoresces in the near-infrared range. The lead indication is lung cancer. The phase 2 VISUALIZE trial completed enrolment in November 2024 and 2025 results showed improved tumour visibility during lung surgery; the FDA granted Fast Track designation in January 2025 and the pivotal phase 3 VISUALIZE 2 study began in March 2026. The company states it has raised more than USD 34 million; SEC Form D filings record equity sales of USD 21.5 million in 2022 and USD 18.7 million in October 2025 plus smaller convertible note offerings. Abenacianine is investigational and not approved for any indication.
Headquarters
Minneapolis, MN, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
top- Investor names are shown as logos on the investors page and could not be read from the fetched text, so investors is empty. Named round letters (Series A/B) were not found in press releases; Form D totals are used instead. The cathepsin mechanism is from general knowledge of VGT-309 rather than the fetched pages. Founding year not stated.
Similar pages
- TrialGleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
- TechnologyQuantum-dot and molecular ultrasound imaging agents
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
- IdeaReal-time margin assessment and image-guided surgery as the global standard
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
- CompanyOn Target Laboratories
Shares Optical & fluorescence imaging, Fluorescence-guided surgery, Non-small-cell lung cancer.
- IdeaA pragmatic trial network for intraoperative margin tools, paid on margin reduction
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
- Treatment5-Aminolevulinic acid (oral, for glioma surgery)
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
- CompanyLumicell
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
- InstitutionChao Family Comprehensive Cancer Center, UC Irvine
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.